Participated · Series A · Dec 2025

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Participated · Series A · Sep 2024

HPC-AI Tech builds AI software infrastructure and video-generation tools, including the open-source projects Colossal-AI and Open-Sora. Colossal-AI enables enterprises to scale large AI workloads like GPT and LLaMA, while Open-Sora focuses on efficient, accessible video generation. The company operates two commercial platforms: hpc-ai.com for model training, fine-tuning, and deployment, and video-ocean.com for producing short-form to full-length videos. Founded by Yang You, a Presidential Young Professor at the National University of Singapore, HPC-AI Tech serves a roster of 50 key clients including four Fortune 500 companies and firms such as AWS, Alibaba, IBM, Intel, and Oracle. The company recently raised $50M in a Series A and intends to use the proceeds to accelerate platform development and grow its client base to 300 within three years. HPC-AI Tech develops Colossal-AI, an integrated large-scale model training system that applies efficient parallelization techniques to accelerate distributed multi-GPU model training. The system is designed to promote deployment of large AI models and deliver lower-cost AI solutions for enterprises. Colossal-AI has established cooperation with manufacturers and open-source communities across autonomous driving, cloud computing, biotech, chip design, and smart retail. The company plans to use the financing to recruit talent and expand its business reach. HPC-AI Tech was founded in Beijing in 2021 and has established an overseas R&D center in Singapore. The firm is focused on serving the enterprise AI market.

Participated · Equity · May 2024

有鹿机器人 was founded in 2023 by Dr. Chen Junbo, the former head of Alibaba Damo Academy's robotics lab, and focuses on building a universal robot brain for embodied intelligence. The company developed the second-generation LPLM large-model family (LPLM-10B published jointly with Alibaba Cloud Tongyi Qianwen) that fuses language models with physical-world reasoning to address latency, accuracy, and generalization issues. LPLM is positioned as a cross-modal, cross-scenario foundational model intended to work across wheeled, hybrid, and humanoid robots. In March the company launched Master2000, a hardware+software, plug-and-play general embodied brain designed to speed intelligent upgrades of professional equipment. Within two months Master2000 moved from customer validation to a confirmed order exceeding ¥10 million and has entered mass production and delivery. The company emphasizes rapid commercial deployment to collect real-world physical data as a core R&D strategy and has disclosed financing of over ¥100 million to support commercialization and scaling.

Participated · Series B · Mar 2024

中博瑞康 is a provider of cell immunotherapy products and testing services targeting tumors, cardiovascular and cerebrovascular diseases, immune diseases and age-related conditions. The company has developed multiple cell immunotherapy products based on ACTL (targeted antitumor cell immunity) and EAAL (amplified activated autologous lymphocyte) technologies. It also offers tumor antigen testing and early cancer screening services including circulating tumor cell and circulating tumor DNA detection. The firm’s offerings span screening, diagnosis, treatment and health management. Recent financing will be used to build a modern production system, strengthen R&D and global registration capabilities, and accelerate expansion into key global markets.

Participated · Series B · Feb 2024

Heqirui Pharmaceutical is a science-driven clinical-stage innovative biopharmaceutical company with R&D bases and offices in Beijing, Shanghai and Nanjing. The company was founded on translational research led by Professor Xiao Ruiping and his team at Peking University's Future Technology Institute. Heqirui focuses on women's health, endocrine and cardiovascular disease areas and is building a diversified pipeline to address unmet clinical needs. Its development model combines in-house R&D with patent in-licensing. The core pipeline includes HMI-115, a monoclonal antibody currently conducting two international Phase II clinical studies. The company recently completed a nearly RMB 200 million B+ financing to support HMI-115's international trials and continued development of other product lines. Hope Medicine Inc. (HopeMed) is a global, science-driven innovative biopharmaceutical company founded by Professor Rui‑Ping Xiao with R&D bases and offices in Nanjing, Shanghai, and Beijing. The company focuses on first-in-class drugs in women's health, endocrinology, and cardiovascular areas through independent R&D and license‑in models. Its pipeline includes HMI‑115, a prolactin receptor antibody in-licensed from Bayer for androgenic alopecia and endometriosis; HMI‑115 completed Phase I trials in the EU with positive safety results. HopeMed plans to launch global multi-center Phase II (MRCT) trials for androgenic alopecia and endometriosis and to advance commercial product development. The company emphasizes building an international multidisciplinary team and strengthening global intellectual property to address unmet medical needs. HopeMed completed a significant Series B financing to support its upcoming international clinical studies and further development of its pipeline.